synergistic effect of geranylgeranyltransferase inhibitor, ggti, and docetaxel on the growth of prostate cancer cells协同效应的geranylgeranyltransferase抑制剂、ggti和多烯紫杉醇对前列腺癌细胞的生长.pdfVIP

Hindawi Publishing Corporation Prostate Cancer Volume 2012, Article ID 989214, 6 pages doi:10.1155/2012/989214 Research Article Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells Bin Han, Naohiro Fujimoto, Mizuki Kobayashi, and Tetsuro Matsumoto Department of Urology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, Japan Correspondence should be addressed to Naohiro Fujimoto, n-fuji@med.uoeh-u.ac.jp Received 13 January 2011; Accepted 8 March 2011 Academic Editor: Jeanny B. Aragon-Ching Copyright © 2012 Bin Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears following those treatments. It is urgently required to identify better or alternative therapeutic strategies. The purpose of this study was to confirm the anti-cancer activity of zoledronic acid (Zol) and determine whether inhibition of geranylgeranylation in the mevalonate pathway could be a molecular target of prostate cancer treatment. We examined the growth inhibitory effect of Zol in prostate cancer cells (LNCaP, PC3, DU145) and investigated a role of geranylgeranylation in the anticancer activity of Zol. We, then, evaluated the growth inhibitory effect of geranylgeranyltransferase inhibitor (GGTI), and analyze